On March, 31, the fifteenth China Interventional Therapeutics (CIT) was held in Beijing, which was sponsored by Chinese Medical Association and jointly organized by National Center for Cardiovascular Diseases (NCCD), Board of Directors of CIT, Chinese Society of Cardiology of Chinese Medical Association and Cardiovascular Research Foundation (CRF). At the conference, the Boston Scientific declared that the landmark product for cardiac intervention therapy -- SYNERGY, a new-generation gold-chromium-platinum alloy biodegradable polymer coating everolimus eluting coronary stent system has been commercially available in China. The stent not only has the ultra-thin stent strut, but also realizes the synchronous of drug release and polymeric carrier degradation. In this way, it helps to rapidly heal the coronary arteries and reduce the incidence of thrombosis, effectively reducing the complications and facilitates the progress of the coronary interventional treatment in China.